AUAUniversity

2019 AUA Annual Meeting Presidential Address

Robert Flanigan, MD, FACS

Loyola University Chicago Stritch School of Medicine

2018 AUA Annual Meeting Presidential Address

J. Brantley Thrasher, MD, FACS

Department of Urology, University of Kansas Health System

2017 AUA Annual Meeting Presidential Address

Urology: A Personal Perspective

Richard K. Babayan, MD, FACS

2016 AUA Annual Meeting Presidential Address

William F. Gee, MD

Lexington, KY

Co-Host: Jay Raman, MD, FACS

At the conclusion of these activities, participants will be able to:

1. Review the mechanisms of action, efficacy, and safety of currently available targeted treatment of RCC.

2. Facilitate discussions with patients and caregivers regarding RCC treatment options.

CME Available: auau.auanet.org/node/26091

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

Co-Host: Yair Lotan, MD

At the conclusion of these activities, participants will be able to:

1. Evaluate treatment plans including the sequencing and combination of treatment options for individual patients.

2. Facilitate discussions with patients and caregivers regarding of bladder cancer treatment options.

CME Available: auau.auanet.org/node/26075

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

Co-Host: Brian M. Shuch, MD

At the conclusion of these activities, participants will be able to:

1. Describe a patient-specific treatment plan that optimizes the use of targeted and immunological agents for the treatment of kidney cancer.

2. Explain best practices in RCC patient selection for various treatment options

CME Available: https://auau.auanet.org/node/26099

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

Co-Host: Alexander Kutikov, MD, FACS

At the conclusion of these activities, participants will be able to:

1. Discuss the evolving landscape of adjuvant therapy for the treatment of RCC.

2. Identify best practices for risk assessment and patient selection for adjuvant RCC therapy.

3. Differentiate the roles of urologist and medical oncologist in the care of patients with RCC.

CME Available: auau.auanet.org/node/26087

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

Co-Host: Alicia K. Morgans, MD, MPH

At the conclusion of these activities, participants will be able to:

1. Recognize cardiovascular comorbidities and describe their management in the context of prostate cancer treatment.

2. Differentiate the roles of the urologist, other specialists and primary care providers in the care of patients with prostate cancer.

CME Available: https://auau.auanet.org/node/26059

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma

Co-Host: Brian Shuch, MD

At the conclusion of these activities, participants will be able to:

1. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men.

2. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results.

3. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors.

CME Available: https://auau.auanet.org/node/26054

This educational series is supported by independent educational grants from:

Amgen

Astellas

AstraZeneca

Bristol-Myers Squibb

Genomic Health

Merck

Pfizer, Inc.

Sanofi Genzyme

UroGen Pharma